Key Points
COPENHAGEN, Nov 7 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions from Nov. 11-13...
Novo's SELECT trial earlier this year concluded that the highly effective Wegovy obesity treatment also had a clear cardiovascular benefit...
"These data build upon our unique understanding and expertise in diabetes and obesity, and we are excited about what they could mean for people with cardiometabolic diseases, including those who may be at higher risk for cardiovascular events," a Novo spokesperson said in a statement...
You might be interested in
Novo Nordisk to buy Cardior Pharma for up to $1 billion
26, Mar, 24Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.